WO2012016133A3 - Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53 - Google Patents

Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53 Download PDF

Info

Publication number
WO2012016133A3
WO2012016133A3 PCT/US2011/045876 US2011045876W WO2012016133A3 WO 2012016133 A3 WO2012016133 A3 WO 2012016133A3 US 2011045876 W US2011045876 W US 2011045876W WO 2012016133 A3 WO2012016133 A3 WO 2012016133A3
Authority
WO
WIPO (PCT)
Prior art keywords
glioblastoma
treatment
kinase inhibitors
ros1 kinase
deficient cancers
Prior art date
Application number
PCT/US2011/045876
Other languages
English (en)
Other versions
WO2012016133A2 (fr
Inventor
Dorre Grueneberg
Ed Harlow
Jun XIAN
Original Assignee
President And Fellows Of Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by President And Fellows Of Harvard College filed Critical President And Fellows Of Harvard College
Publication of WO2012016133A2 publication Critical patent/WO2012016133A2/fr
Publication of WO2012016133A3 publication Critical patent/WO2012016133A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

L'invention concerne des méthodes et des compositions pour le traitement de tumeurs, notamment des glioblastomes, à l'aide d'inhibiteurs de ROS1. Les cellules cancéreuses sont préférentiellement inhibées par rapport aux cellules normales par l'inhibition de ROS1 kinases tumorales qui sont nécessaires pour la croissance de cellules tumorales, mais pas pour des cellules normales.
PCT/US2011/045876 2010-07-29 2011-07-29 Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53 WO2012016133A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40057810P 2010-07-29 2010-07-29
US61/400,578 2010-07-29

Publications (2)

Publication Number Publication Date
WO2012016133A2 WO2012016133A2 (fr) 2012-02-02
WO2012016133A3 true WO2012016133A3 (fr) 2012-04-26

Family

ID=45530737

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/045876 WO2012016133A2 (fr) 2010-07-29 2011-07-29 Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53

Country Status (1)

Country Link
WO (1) WO2012016133A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
SG184987A1 (en) 2010-04-22 2012-11-29 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
CA2853024C (fr) 2011-11-11 2017-08-22 Pfizer Inc. 2-thiopyrimidinones
TWI622578B (zh) 2011-12-21 2018-05-01 諾維拉治療公司 Ｂ型肝炎抗病毒劑
SI2838998T1 (en) 2012-04-18 2018-04-30 Cell Signaling Technology, Inc. EGFR AND ROS1 PRI CRAK
BR112015004192B1 (pt) 2012-08-28 2021-02-09 Janssen Sciences Ireland Uc sulfamoíl-arilamidas, composição farmacêutica que os compreende e uso das mesmas no tratamento da hepatite b
WO2014131847A1 (fr) 2013-02-28 2014-09-04 Janssen R&D Ireland Sulfamoyl-arylamides et leur utilisation en tant que médicaments pour le traitement de l'hépatite b
WO2014165128A2 (fr) 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Agents antiviraux contre l'hépatite b
WO2014141129A2 (fr) 2013-03-14 2014-09-18 Grueneberg Dorre A Nouveaux procédés, composés et compositions pour l'inhibition de ros
BR112015025052A2 (pt) 2013-04-03 2021-07-06 Janssen Sciences Ireland Uc derivados de n-fenil-carboxamida e o seu uso como medicamentos para o tratamento da hepatite b
DE102013008118A1 (de) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
EP3357906B1 (fr) 2013-07-25 2019-12-04 Janssen Sciences Ireland Unlimited Company Dérivés de pyrrolamide substitués de glyoxamide et leur utilisation comme médicaments pour le traitement de l'hépatite b
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
CA2926950C (fr) 2013-10-10 2022-10-11 Eastern Virginia Medical School Derives de 4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide commeinhibiteurs puissants et selectifs de 12-lipoxygenase
CN105636945B (zh) 2013-10-14 2017-11-17 卫材R&D管理有限公司 选择性取代的喹啉化合物
AU2014334554B2 (en) 2013-10-14 2018-12-06 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
MX368158B (es) 2013-10-23 2019-09-20 Janssen Sciences Ireland Uc Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
WO2015120178A1 (fr) 2014-02-05 2015-08-13 Novira Therapeutics, Inc. Polythérapie pour le traitement d'infections par le vhb
CN105980378B (zh) 2014-02-06 2019-09-27 爱尔兰詹森科学公司 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
ME03580B (fr) 2014-02-13 2020-07-20 Incyte Corp Cyclopropylamines en tant qu'inhibiteurs de lsd1
CA2939082C (fr) 2014-02-13 2022-06-07 Incyte Corporation Cyclopropylamines en tant qu'inhibiteurs de lsd1
ES2672797T3 (es) 2014-02-13 2018-06-18 Incyte Corporation Ciclopropilaminas como inhibidores de LSD1
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
PL3925607T3 (pl) 2014-04-15 2023-10-30 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
WO2016007731A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines et imidazopyrazines à utiliser en tant qu'inhibiteurs de lsd1
WO2016007727A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1
WO2016007722A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines et triazolopyrazines utilisables comme inhibiteurs de lsd1
EP3180086A4 (fr) 2014-07-23 2017-12-27 Northeastern University Ligands pour la sous-unité alpha-7 des récepteurs nicotiniques de l'acétylcholine et méthodes de traitement de troubles neurologiques et inflammatoires
CN107847762A (zh) 2015-03-19 2018-03-27 诺维拉治疗公司 氮杂环辛烷和氮杂环壬烷衍生物以及治疗乙型肝炎感染的方法
TWI714567B (zh) 2015-04-03 2021-01-01 美商英塞特公司 作為lsd1抑制劑之雜環化合物
EP3292109A1 (fr) 2015-05-05 2018-03-14 Pfizer Inc 2-thiopyrimidinones
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CR20180152A (es) 2015-08-12 2018-08-09 Incyte Corp Sales de un inhibidor de lsd1
EP3356328A1 (fr) 2015-09-29 2018-08-08 Novira Therapeutics, Inc. Formes cristallines d'un agent antiviral de l'hépatite b
EP3365340B1 (fr) 2015-10-19 2022-08-10 Incyte Corporation Composés hétérocycliques utilisés comme immunomodulateurs
MD3377488T2 (ro) 2015-11-19 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
SG11201805300QA (en) 2015-12-22 2018-07-30 Incyte Corp Heterocyclic compounds as immunomodulators
SG11201808949SA (en) 2016-04-15 2018-11-29 Novira Therapeutics Inc Combinations and methods comprising a capsid assembly inhibitor
MX2018012901A (es) 2016-04-22 2019-06-06 Incyte Corp Formulaciones de inhibidor de demetilasa 1 especifica para lisina (lsd1).
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
AU2017275657B2 (en) 2016-06-02 2021-08-19 Novartis Ag Potassium channel modulators
CA3028685A1 (fr) 2016-06-20 2017-12-28 Incyte Corporation Composes heterocycliques utilises comme immunomodulateurs
US20180016260A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
ES2934230T3 (es) 2016-12-22 2023-02-20 Incyte Corp Derivados de benzooxazol como inmunomoduladores
HRP20221216T1 (hr) 2016-12-22 2022-12-23 Incyte Corporation Derivati tetrahidro imidazo[4,5-c]piridina kao induktori internalizacije pd-l1
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
US9975886B1 (en) 2017-01-23 2018-05-22 Cadent Therapeutics, Inc. Potassium channel modulators
BR112019021400A2 (pt) 2017-04-26 2020-04-28 Basilea Pharmaceutica International AG processos para a preparação de furazanobenzimidazóis e formas cristalinas dos mesmos
EP3615532A4 (fr) 2017-04-28 2020-11-18 Dana Farber Cancer Institute, Inc. Inhibiteurs de trim33 et méthodes d'utilisation
SG11202000230VA (en) 2017-07-11 2020-02-27 Vertex Pharma Carboxamides as modulators of sodium channels
JP2021517893A (ja) 2018-03-13 2021-07-29 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 血漿カリクレインのインヒビターとしての置換されたイミダゾピリジン及びその使用
AU2019235522A1 (en) 2018-03-14 2020-09-03 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
FI3774791T3 (fi) 2018-03-30 2023-03-21 Incyte Corp Heterosyklisiä yhdisteitä immunomodulaattoreina
CN112752756A (zh) 2018-05-11 2021-05-04 因赛特公司 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
WO2020047198A1 (fr) 2018-08-31 2020-03-05 Incyte Corporation Sels d'un inhibiteur de lsd1 et leurs procédés de préparation
US11459340B2 (en) 2018-09-18 2022-10-04 Nikang Therapeutics, Inc. Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
EA202191890A1 (ru) 2019-01-18 2022-02-03 Астразенека Аб Ингибиторы pcsk9 и способы их применения
MA55020A (fr) 2019-02-22 2021-12-29 Janssen Sciences Ireland Unlimited Co Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
AR119732A1 (es) 2019-05-06 2022-01-05 Janssen Sciences Ireland Unlimited Co Derivados de amida útiles en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
TW202115059A (zh) 2019-08-09 2021-04-16 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽
US11787796B2 (en) 2019-09-18 2023-10-17 Takeda Pharmaceutical Company Limited Plasma Kallikrein inhibitors and uses thereof
WO2021055589A1 (fr) 2019-09-18 2021-03-25 Shire Human Genetic Therapies, Inc. Inhibiteurs hétéroaryles de la kallicréine plasmatique
AU2020357514A1 (en) 2019-09-30 2022-04-07 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
WO2021096849A1 (fr) 2019-11-11 2021-05-20 Incyte Corporation Formes salines et cristallines d'un inhibiteur de pd-1/pd-l1
TW202128675A (zh) 2019-12-06 2021-08-01 美商維泰克斯製藥公司 作為鈉通道調節劑之經取代四氫呋喃
CN111205303B (zh) * 2020-03-03 2021-04-27 四川大学 噻吩并[2,3-d]嘧啶基异羟肟酸衍生物及其用途
AU2021267373A1 (en) 2020-05-06 2022-12-08 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
WO2021243001A1 (fr) * 2020-05-27 2021-12-02 Constellation Pharmaceuticals, Inc. Benzamides substitués en tant que modulateurs de trex1
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
IL302590A (en) 2020-11-06 2023-07-01 Incyte Corp Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
US11827627B2 (en) 2021-06-04 2023-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
EP4367112A1 (fr) 2021-07-09 2024-05-15 Plexium, Inc. Composés aryle et compositions pharmaceutiques modulant l'ikzf2
WO2023075285A1 (fr) * 2021-10-27 2023-05-04 고려대학교 산학협력단 Composition destinée à la prévention ou au traitement de la maladie de graves comprenant un composé contenant une structure imidazopyridine en tant que principe actif
WO2023086319A1 (fr) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-hetero-aryloxy-benzimidazoles et azabenzimidazoles en tant qu'inhibiteurs de jak2

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009140128A2 (fr) * 2008-05-13 2009-11-19 Irm Llc Composés et compositions servant d'inhibiteurs de kinases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009140128A2 (fr) * 2008-05-13 2009-11-19 Irm Llc Composés et compositions servant d'inhibiteurs de kinases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BYUNG SUN PARK ET AL.: "Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 19, no. 16, 2009, pages 4720 - 4723, XP026419064 *
HYUN JUNG JUN ET AL.: "Epigenetic Regulation of c-ROS receptor tyrosine kinase expression in Malignant gliomas", CANCER RESEARCH, vol. 69, no. 6, 2009, pages 2180 - 2184 *
IBRABIM MUSTAFA EL-DEEB ET AL.: "ROS Receptor Tyrosine Kinase: A New Potential target for Anticancer Drugs", MEDICINAL RESEARCH REVIEWS, vol. 31, no. 5, 2011, pages 794 - 818 *
IBRAHIM M. EL-DEEB ET AL.: "Design, synthesis, screening, and molecular modeling study of a new series or ROS1 receptor tyrosine kinase inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 19, no. 19, 2009, pages 5622 - 5626 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors

Also Published As

Publication number Publication date
WO2012016133A2 (fr) 2012-02-02

Similar Documents

Publication Publication Date Title
WO2012016133A3 (fr) Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53
WO2010141738A3 (fr) Compositions et procédé pour inhiber la croissance d'une tumeur
MX2015007205A (es) Inhibidores de la desmetilasa de histona.
NZ718190A (en) Substituted quinazolines for inhibiting kinase activity
SA515360657B1 (ar) مثبطات ديميثيلاز هيستون
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
WO2013023084A3 (fr) Procédés et compositions pour l'inhibition de la croissance et/ou de la prolifération de cellules tumorales activées par myc
MX2011007420A (es) Compuestos, composiciones y metodos para prevenir la metastasis de las celulas cancerigenas.
WO2011112953A3 (fr) Utilisation d'inhibiteurs d'erbb3 dans le traitement de cancers du sein triples négatifs et de type basal
WO2012015914A3 (fr) Modificateurs du récepteur d'hydrocarbure aryle (ahr) en tant que nouveaux produits thérapeutiques anticancéreux
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
WO2011037643A3 (fr) Compositions et procédés de détection et de traitement de carcinomes de la prostate
TNSN08375A1 (en) Quinazolines for pdk1 inhibition
WO2012170827A3 (fr) Pyrazolopyrimidines et hétérocycles associés comme inhibiteurs de ck2
PH12014502047B1 (en) Treatment of cancer with tor kinase inhibitors
MX357502B (es) Derivados de pirrolotriazinona.
MX2011012369A (es) Pirazolopirimidinas y heterociclos relacionados como inhibidores de cinasa.
WO2013093508A3 (fr) Inhibiteurs de la voie wnt
WO2012135641A3 (fr) Inhibiteurs de kinase aurora et procédés pour les fabriquer et les utiliser
WO2011146568A8 (fr) Prédiction de réponses à un inhibiteur de her
WO2011159685A3 (fr) Inhibition de l'interaction de la protéine wdr5 avec ses partenaires de liaison et méthodes thérapeutiques associées
NZ700612A (en) Methods and compositions for treating ewings sarcoma family of tumors
WO2010104598A3 (fr) Inhibiteurs de la liaison à une protéine kinase
MX336761B (es) Compuestos para el tratamiento de cancer.
WO2014062878A3 (fr) Traitement du cancer avec des inhibiteurs de kinase tor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11813240

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11813240

Country of ref document: EP

Kind code of ref document: A2